(0.18%) 5 189.80 points
(0.17%) 38 920 points
(0.09%) 16 363 points
(-0.46%) $78.12
(0.09%) $2.20
(-0.17%) $2 327.30
(0.27%) $27.69
(2.40%) $988.10
(-0.12%) $0.927
(0.35%) $10.86
(0.00%) $0.796
(0.22%) $91.55
0.80% € 151.34
Live Chart Being Loaded With Signals
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection...
Stats | |
---|---|
Dzisiejszy wolumen | 508.00 |
Średni wolumen | 674.00 |
Kapitalizacja rynkowa | 267.97B |
EPS | €0 ( 2024-04-26 ) |
Następna data zysków | ( €0 ) 2024-07-24 |
Last Dividend | €1.480 ( 2023-07-13 ) |
Next Dividend | €0 ( N/A ) |
P/E | 48.20 |
ATR14 | €0.443 (0.29%) |
Abbvie Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Abbvie Inc Finanse
Annual | 2023 |
Przychody: | €54.32B |
Zysk brutto: | €33.90B (62.42 %) |
EPS: | €2.75 |
FY | 2023 |
Przychody: | €54.32B |
Zysk brutto: | €33.90B (62.42 %) |
EPS: | €2.75 |
FY | 2022 |
Przychody: | €58.05B |
Zysk brutto: | €40.64B (70.00 %) |
EPS: | €6.69 |
FY | 2021 |
Przychody: | €56.20B |
Zysk brutto: | €38.75B (68.96 %) |
EPS: | €6.92 |
Financial Reports:
No articles found.
Abbvie Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€1.410 (N/A) |
€1.410 (N/A) |
€1.480 (N/A) |
€1.480 (N/A) |
€1.480 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.570 | 2016-07-13 |
Last Dividend | €1.480 | 2023-07-13 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | €24.73 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.49 | -- |
Div. Sustainability Score | 4.84 | |
Div.Growth Potential Score | 6.92 | |
Div. Directional Score | 5.88 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
KEL.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
UN9.DE | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
DB1.DE | Ex Dividend Junior | 2023-05-17 | Annually | 0 | 0.00% | |
MUM.DE | Ex Dividend Knight | 2023-05-12 | Annually | 0 | 0.00% | |
2OY.DE | Ex Dividend Knight | 2023-08-30 | Quarterly | 0 | 0.00% | |
YCP.DE | Ex Dividend King | 2023-09-27 | Bi-Monthly | 0 | 0.00% | |
EVD.DE | Ex Dividend Junior | 2023-05-17 | Sporadic | 0 | 0.00% | |
PER.DE | Ex Dividend Knight | 2023-07-05 | Annually | 0 | 0.00% | |
AHOG.DE | Ex Dividend Knight | 2023-08-11 | Semi-Annually | 0 | 0.00% | |
HAW.DE | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.110 | 1.500 | 7.80 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.524 | 1.500 | 5.28 | 7.93 | [0.1 - 1] |
payoutRatioTTM | 1.315 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 8.88 | 1.000 | 7.82 | 7.82 | [3 - 30] |
operatingCashFlowPerShareTTM | 10.49 | 2.00 | 6.50 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 10.15 | 2.00 | 4.93 | 9.85 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.624 | 1.000 | 2.93 | 2.93 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.247 | 1.000 | 7.06 | 7.06 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.84 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 47.98 | 1.000 | 5.25 | 0 | [1 - 100] |
returnOnEquityTTM | 0.524 | 2.50 | 6.97 | 7.93 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 10.15 | 2.00 | 6.62 | 9.85 | [0 - 30] |
dividendYielPercentageTTM | 3.75 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 10.49 | 2.00 | 6.50 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.315 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 18.18 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.343 | 1.000 | 3.93 | 0 | [0.1 - 0.5] |
Total Score | 6.92 |
Abbvie Inc
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej